Long-term impact of early initiation of enzyme replacement therapy in 34 MPS VI patients
Carregando...
Data
2021
Data de publicação:
Autores IPEN
Orientador
Título da Revista
ISSN da Revista
Título do Volume
É parte de
É parte de
É parte de
Molecular Genetics and Metabolism
ODS
Exportar
Resumo
Patients with mucopolysaccharidosis type VI (MPS VI) present with a wide range of disease severity and clinical manifestations, with significant functional impairment and shortened lifespan. Enzyme replacement therapy (ERT) with galsulfase has been shown to improve clinical and biochemical parameters including patient survival, quality of life and growth. The present study is a resurvey of 34 Brazilian MPS VI patients with rapidly progressive disease (classical phenotype) who initiated ERT with galsulfase under five years of age and had been on ERT until data collection in 2019, with few exceptions (n = 4 patients who died before 2019). Anthropometric measures, urinary glycosaminoglycans, and data regarding cardiac, orthopedic, neurologic, sleep apnea, hearing and ophthalmologic outcomes were filled in by specialists. Pubertal development, clinical complications, hospitalizations, and surgeries were also assessed. In this resurvey study, treatment with galsulfase has shown to be safe and well tolerated in MPS VI patients who initiated ERT under the age of 5 years and who have been undergoing ERT for approximately 10 years. Mortality rate suggests that early initiation of ERT may have a positive impact on patients' survival, improving but not preventing disease progression and death. MPS VI patients on ERT also showed improved growth velocity and the pubertal development was normal in all surviving patients. Follow-up data on pneumonia and hospitalization suggest that early ERT may have a protective effect against major respiratory complications. Cardiac valve disease progressed since their prior evaluation and spinal cord compression was observed in a large number of patients, suggesting that these disease complications were not modified by ERT.
Como referenciar
HOROVITZ, DAFNE D.G.; LEAO, EMILIA K.E.A.; RIBEIRO, ERLANE M.; MARTINS, ANA M.; BARTH, ANNELIESE L.; NERI, JOAO I.C.F.; KERSTENETZKY, MARCELO; SIQUEIRA, ANA C.M.; RIBEIRO, BETHANIA F.R.; KIM, CHONG A.; SANTOS, FRANCISCA C.; FRANCO, JOSE F.S.; LICHTVAN, LENIZA C.L.; GIULIANI, LIANE R.; RODRIGUES, MARIA do C.S.; BONATTI, RENATA C.F.; TEIXEIRA, THAIS B.; GONCALVES, ALEXANDRA; LOURENCO, CHARLES M.; PEREIRA, ANE S.S.; ACOSTA, ANGELINA X. Long-term impact of early initiation of enzyme replacement therapy in 34 MPS VI patients: a resurvey study. Molecular Genetics and Metabolism, v. 133, n. 1, p. 94-99, 2021. DOI: 10.1016/j.ymgme.2021.02.006. Disponível em: http://repositorio.ipen.br/handle/123456789/32367. Acesso em: 10 May 2024.
Esta referência é gerada automaticamente de acordo com as normas do estilo IPEN/SP (ABNT NBR 6023) e recomenda-se uma verificação final e ajustes caso necessário.